236 related articles for article (PubMed ID: 25364261)
1. Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives.
Chen GX; Zhang S; He XH; Liu SY; Ma C; Zou XP
Onco Targets Ther; 2014; 7():1901-9. PubMed ID: 25364261
[TBL] [Abstract][Full Text] [Related]
2. Advances in adenovirus-mediated p53 cancer gene therapy.
Tazawa H; Kagawa S; Fujiwara T
Expert Opin Biol Ther; 2013 Nov; 13(11):1569-83. PubMed ID: 24107178
[TBL] [Abstract][Full Text] [Related]
3. Role of Adenoviruses in Cancer Therapy.
Tseha ST
Front Oncol; 2022; 12():772659. PubMed ID: 35756634
[TBL] [Abstract][Full Text] [Related]
4. INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy--Introgen, RPR/INGN 201.
BioDrugs; 2003; 17(3):216-22. PubMed ID: 12749760
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus-mediated expression of p53 or p21 in a papillary serous endometrial carcinoma cell line (SPEC-2) results in both growth inhibition and apoptotic cell death: potential application of gene therapy to endometrial cancer.
Ramondetta L; Mills GB; Burke TW; Wolf JK
Clin Cancer Res; 2000 Jan; 6(1):278-84. PubMed ID: 10656459
[TBL] [Abstract][Full Text] [Related]
6. Late expression of p53 from a replicating adenovirus improves tumor cell killing and is more tumor cell specific than expression of the adenoviral death protein.
Sauthoff H; Pipiya T; Heitner S; Chen S; Norman RG; Rom WN; Hay JG
Hum Gene Ther; 2002 Oct; 13(15):1859-71. PubMed ID: 12396618
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer.
Wolf JK; Bodurka DC; Gano JB; Deavers M; Ramondetta L; Ramirez PT; Levenback C; Gershenson DM
Gynecol Oncol; 2004 Aug; 94(2):442-8. PubMed ID: 15297186
[TBL] [Abstract][Full Text] [Related]
8. Characterization of replication-competent adenovirus isolates from large-scale production of a recombinant adenoviral vector.
Zhu J; Grace M; Casale J; Chang AT; Musco ML; Bordens R; Greenberg R; Schaefer E; Indelicato SR
Hum Gene Ther; 1999 Jan; 10(1):113-21. PubMed ID: 10022536
[TBL] [Abstract][Full Text] [Related]
9. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
10. Combined radiation and p53 gene therapy of malignant glioma cells.
Badie B; Goh CS; Klaver J; Herweijer H; Boothman DA
Cancer Gene Ther; 1999; 6(2):155-62. PubMed ID: 10195882
[TBL] [Abstract][Full Text] [Related]
11. Mesenchymal stem cell-mediated delivery of therapeutic adenoviral vectors to prostate cancer.
Muhammad T; Sakhawat A; Khan AA; Ma L; Gjerset RA; Huang Y
Stem Cell Res Ther; 2019 Jun; 10(1):190. PubMed ID: 31238944
[TBL] [Abstract][Full Text] [Related]
12. Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma.
Geoerger B; van Beusechem VW; Opolon P; Morizet J; Laudani L; Lecluse Y; Barrois M; Idema S; Grill J; Gerritsen WR; Vassal G
J Gene Med; 2005 May; 7(5):584-94. PubMed ID: 15651070
[TBL] [Abstract][Full Text] [Related]
13. Toxicology profiles of a novel p53-armed replication-competent oncolytic adenovirus in rodents, felids, and nonhuman primates.
Su C; Cao H; Tan S; Huang Y; Jia X; Jiang L; Wang K; Chen Y; Long J; Liu X; Wu M; Wu X; Qian Q
Toxicol Sci; 2008 Nov; 106(1):242-50. PubMed ID: 18703561
[TBL] [Abstract][Full Text] [Related]
14. [Molecular surgery for human colorectal cancer with tumor suppressor p53 gene transfer].
Fujiwara T; Tanaka N
Nihon Geka Gakkai Zasshi; 1998 Jul; 99(7):463-8. PubMed ID: 9742529
[TBL] [Abstract][Full Text] [Related]
15. Clinical study of recombinant adenovirus-p53 (Adp53) combined with hyperthermia in advanced cancer (a report of 15 cases).
Zhang S; Xu G; Liu C; Xiao S; Sun Y; Su X; Cai Y; Li D; Xu B
Int J Hyperthermia; 2005 Nov; 21(7):631-6. PubMed ID: 16304714
[TBL] [Abstract][Full Text] [Related]
16. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant glioma.
Geoerger B; Vassal G; Opolon P; Dirven CM; Morizet J; Laudani L; Grill J; Giaccone G; Vandertop WP; Gerritsen WR; van Beusechem VW
Cancer Res; 2004 Aug; 64(16):5753-9. PubMed ID: 15313916
[TBL] [Abstract][Full Text] [Related]
18. Recombinant E1-deleted adenovirus-mediated gene therapy for cancer: efficacy studies with p53 tumor suppressor gene and liver histology in tumor xenograft models.
Nielsen LL; Gurnani M; Syed J; Dell J; Hartman B; Cartwright M; Johnson RC
Hum Gene Ther; 1998 Mar; 9(5):681-94. PubMed ID: 9551616
[TBL] [Abstract][Full Text] [Related]
19. The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic.
Zhang WW; Li L; Li D; Liu J; Li X; Li W; Xu X; Zhang MJ; Chandler LA; Lin H; Hu A; Xu W; Lam DM
Hum Gene Ther; 2018 Feb; 29(2):160-179. PubMed ID: 29338444
[TBL] [Abstract][Full Text] [Related]
20. The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity.
Wildner O; Morris JC
Cancer Res; 2000 Aug; 60(15):4167-74. PubMed ID: 10945625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
